ATE260099T1 - Neue hemmern von fortgeschrittenen glykosilierung-endprodukten - Google Patents

Neue hemmern von fortgeschrittenen glykosilierung-endprodukten

Info

Publication number
ATE260099T1
ATE260099T1 AT00920121T AT00920121T ATE260099T1 AT E260099 T1 ATE260099 T1 AT E260099T1 AT 00920121 T AT00920121 T AT 00920121T AT 00920121 T AT00920121 T AT 00920121T AT E260099 T1 ATE260099 T1 AT E260099T1
Authority
AT
Austria
Prior art keywords
proteins
inhibit
glycation
compounds
aging
Prior art date
Application number
AT00920121T
Other languages
English (en)
Inventor
Samuel Rahbar
Iraj Lalezari
Original Assignee
Hope City
Proscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City, Proscience Corp filed Critical Hope City
Application granted granted Critical
Publication of ATE260099T1 publication Critical patent/ATE260099T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT00920121T 1999-04-05 2000-04-05 Neue hemmern von fortgeschrittenen glykosilierung-endprodukten ATE260099T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12783599P 1999-04-05 1999-04-05
PCT/US2000/008938 WO2000059875A2 (en) 1999-04-05 2000-04-05 Novel inhibitors of formation of advanced glycation endproducts (age's)

Publications (1)

Publication Number Publication Date
ATE260099T1 true ATE260099T1 (de) 2004-03-15

Family

ID=22432212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920121T ATE260099T1 (de) 1999-04-05 2000-04-05 Neue hemmern von fortgeschrittenen glykosilierung-endprodukten

Country Status (8)

Country Link
US (1) US6337350B1 (de)
EP (1) EP1165064B1 (de)
JP (1) JP5209832B2 (de)
AT (1) ATE260099T1 (de)
AU (1) AU763750B2 (de)
CA (1) CA2368688C (de)
DE (1) DE60008509T2 (de)
WO (1) WO2000059875A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589944B1 (en) * 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US7030133B2 (en) * 1999-04-05 2006-04-18 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
DE10158076B4 (de) * 2001-11-27 2005-09-01 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitungen mit einem Gehalt an Aryl-Ureido-Verbindungen und ihre Verwendung
ATE428412T1 (de) * 2002-02-13 2009-05-15 Vitreo Retinal Technologies In Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten
US20040057949A1 (en) * 2002-09-23 2004-03-25 Depaolis Potito U. Hemodialysis method for improving immune system function
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
ATE446951T1 (de) * 2003-06-10 2009-11-15 Biondi Ricardo Miguel Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung
EP2269601A1 (de) * 2003-10-27 2011-01-05 City of Hope LR-9, LR-74 and LR-90 zur Verwendung in der Behandlung von Diabetes-bedingten Komplikationen
EP1755579A4 (de) * 2004-05-24 2009-06-10 Univ New York Verfahren zur behandlung oder prävention von pathologischen wirkungen einer akuten zunahme von hyperglykämie und/oder einer akuten zunahme von freiem fettsäurefluss
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
EA200800338A1 (ru) * 2005-07-15 2008-08-29 Чакшу Рисерч Инк. Профилактика и лечение офтальмологических осложнений диабета
US8048896B2 (en) * 2005-10-05 2011-11-01 Cell Viable Corporation Methods for inhibiting and breaking AGE complex formation
WO2007044309A2 (en) * 2005-10-05 2007-04-19 Vasix Corporation Device and method for inhibiting age complex formation
US8580854B2 (en) * 2005-11-09 2013-11-12 City Of Hope Methods of suppression of rage gene expression and rage triggered inflammatory genes by selected age-inhibitors
DE102007041232A1 (de) 2007-08-30 2009-03-05 Henkel Ag & Co. Kgaa Verwendung von Sulfonylharnstoffen zur Spaltung von AGEs
US20090023731A1 (en) * 2007-03-22 2009-01-22 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US8124655B2 (en) * 2007-06-15 2012-02-28 City Of Hope Use of LR-90 and LR-102 to overcome insulin resistance
FR2918570B1 (fr) * 2007-07-09 2012-10-05 Engelhard Lyon DIGLYCATION DES AGEs.
DE102007054653A1 (de) 2007-11-14 2009-05-20 Henkel Ag & Co. Kgaa Verwendung von Thioharnstoff-Derivaten zur Spaltung von AGEs
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
EP2261214A1 (de) * 2009-06-12 2010-12-15 Splicos Sas Zusammensetzungen, die zur Behandlung von vorzeitiger Alterung und insbesondere Hutchinson-Gilford-Syndrom von Nutzen sind
FI2440546T3 (fi) 2009-06-12 2023-03-30 Abivax Ennenaikaisen vanhenemisen ja erityisesti progerian hoitamiseen hyödyllisiä yhdisteitä
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
EP2465502A1 (de) 2010-12-15 2012-06-20 Société Splicos Nützliche Verbindungen zur Behandlung von AIDS
US9808434B2 (en) 2011-01-27 2017-11-07 City Of Hope Compound for treating cancer and diabetes
WO2012103523A2 (en) 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells
CN102718727B (zh) * 2011-03-31 2016-04-20 中国医学科学院药物研究所 Gk和ppar双重激动活性的芳基脲类衍生物
CN102718703B (zh) * 2011-03-31 2016-09-14 中国医学科学院药物研究所 Gk和ppar双重激动活性的含有二甲基的芳基脲类衍生物
EP2782902A4 (de) * 2011-11-23 2015-08-26 Jill S Fabricant Derivate aus phenoxyisobuttersäure
EP2757161A1 (de) 2013-01-17 2014-07-23 Splicos miRNA-124 als ein Biomarker für virale Infektion
MX382692B (es) 2013-07-05 2025-03-13 Abivax Compuestos bicíclicos útiles para el tratamiento de enfermedades causadas por retrovirus.
US9827236B2 (en) * 2014-05-11 2017-11-28 Mythri Ambatipudi Method of inhibiting the glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids
EP2974729A1 (de) 2014-07-17 2016-01-20 Abivax Chinolinderivate zur Verwendung bei der Behandlung von Entzündungskrankheiten
CN104961645A (zh) * 2015-07-22 2015-10-07 中国药科大学 苯氧乙酸类衍生物、其制备方法及其作为药物的用途
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
EP3669873A1 (de) 2018-12-20 2020-06-24 Abivax Chinolinderivate zur verwendung bei der behandlung von entzündlichen krankheiten
JP7620629B2 (ja) * 2019-12-02 2025-01-23 アカデミア シニカ ＰＤＩＡ４阻害剤及びβ細胞発症機序を阻害し、糖尿病を治療するためのこのＰＤＩＡ４阻害剤の使用
US20230038360A1 (en) * 2019-12-20 2023-02-09 Basf Se Composition for the treatment of amyloid-beta associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272176A (en) * 1984-03-19 1993-12-21 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
DE3410927A1 (de) 1984-03-24 1985-10-03 Hoechst Ag, 6230 Frankfurt Vollaromatische polyester, verfahren zu ihrer herstellung und entsprechende formkoerper
JPS619227A (ja) * 1984-06-22 1986-01-16 生体機能利用化学品新製造技術研究組合 キンポウゲ科植物の組織培養方法
JPS6222517A (ja) * 1985-07-23 1987-01-30 株式会社ツムラ ウリ科植物不定根の培養方法
JPS6232880A (ja) * 1985-08-06 1987-02-12 Seitai Kinou Riyou Kagakuhin Shinseizou Gijutsu Kenkyu Kumiai キンポウゲ科植物の組織培養方法
US5268500A (en) 1987-06-15 1993-12-07 Montefiore Medical Center Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation
US4921997A (en) 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5093367A (en) 1988-06-15 1992-03-03 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5677330A (en) * 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
WO1995031192A1 (en) * 1994-05-16 1995-11-23 Thomas Jefferson University Method and use of agents to inhibit protein polymerization and methods of identifying these agents
US5962651A (en) * 1995-01-27 1999-10-05 Montefiore Medical Center Modified hemoglobin and its use as a component of an artificial blood substitute
US5602277A (en) 1995-03-30 1997-02-11 Biocryst Pharmaceuticals, Inc. Substituted benzene derivatives useful as neuraminidase inhibitors
US5716987A (en) * 1996-06-21 1998-02-10 Bristol-Myers Squibb Company Prophylactic and therapeutic treatment of skin sensitization and irritation

Also Published As

Publication number Publication date
EP1165064B1 (de) 2004-02-25
JP2002541139A (ja) 2002-12-03
AU4070700A (en) 2000-10-23
EP1165064A2 (de) 2002-01-02
DE60008509D1 (de) 2004-04-01
AU763750B2 (en) 2003-07-31
DE60008509T2 (de) 2004-12-16
CA2368688C (en) 2009-08-11
WO2000059875A3 (en) 2001-03-29
US6337350B1 (en) 2002-01-08
WO2000059875A2 (en) 2000-10-12
JP5209832B2 (ja) 2013-06-12
CA2368688A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
DE60008509D1 (de) Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
ATE361064T1 (de) Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte
WO2000066102A3 (en) Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age&#39;s)
ATE388704T1 (de) Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen
ATE245420T1 (de) Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
Tessier The Maillard reaction in the human body. The main discoveries and factors that affect glycation
DE69507199D1 (de) Heterocyclylcarbonylsubstituierte Benzofuranyl- und -thiophenylalkancarbonsäurederivate
EP1594492A4 (de) Neue hemmer der bildung von ages (advanced glycation endproducts)
NO903325D0 (no) Ensileringssammensetning.
ATE239001T1 (de) Verfahren zur herstellung von triazolinthion- derivaten
US2491646A (en) Process for treating animal materials
Zhao et al. Fructose-mediated damage to lens α-crystallin: prevention by pyruvate
Egan et al. Differential effects of prostaglandin synthetase stimulators on inhibition of cyclooxygenase
Ali et al. Role of natural compounds in the prevention of DNA and proteins damage by glycation
Wang et al. Kinetics of the course of inactivation of aminoacylase by 1, 10-phenanthroline
WO1996021450A3 (en) Bis-[hydrazones]
DE69715218D1 (de) Substituierte imidazoliunsalze und deren verwendung zur hemmung der proteinalterung
Fitzgerald et al. Non-enzymatic glycosylation (or glycation) and inhibition of the pig heart cytosolic aspartate aminotransferase by glyceraldehyde 3-phosphate
KR880003569A (ko) 산성화 마쇄육류의 제조방법 및 그 제품
MX9803898A (es) Metodo y mejorado y agentes para inhibir el envejecimiento de proteina.
Corzo-Martínez et al. Role of pyridoxamine in the formation of the Amadori/Heyns compounds and aggregates during the glycation of β-lactoglobulin with galactose and tagatose
US2433879A (en) Manufacture of amino acid preparations intended for intravenous supply of nutrients
DE68912883D1 (de) Verfahren zur Modifizierung der Produktion von trockenen Getreideprodukten durch Enzymhinzufügung.
US5356895A (en) 1,4 piperizino inhibitors of non-enzymatic cross-linking of proteins
BR9504004A (pt) Composto processo para sua preparação e composição farmacêutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties